DreamPharm Home   About Us Contact Us Products Home


   Lutein-6 and Lutein
  Lutein helps to protect your over-worked
  eyes from aging and environmental harms.


   Milk thistle
  Silymarin helps to protect your liver, an
  over-worked organ.


   Saw palmetto
  A herb that deters prostate enlargement.


   Triple B Super Vision
  Best eye nutritions in one tablet.
  A visionary product for eyes.


   Garlic, Ginger, and Grapeseed Extract
  Majestic trio of garlic, ginger, and grapeseed
  extract. What could be better?


   Ginseng and Ginkgo
  Ginseng and Gingko biloba together, for
   sound body and sound mind.


   Hair Million
Herbal formula for hair loss. Be hairy herbally.


   DHEA
  The hormone of youth and health.


   Coenzyme Q10
  Strong anti-oxidant that does your heart good.


   Sleep Aid herbal formula
  Good sleep, the best medicine.


   Herbal Breath
  Clean and healthy herbal breath.


   Weight loss herbal formula
  Best herbs for PMS and menopause.
  Herbs for women's health.


   Ginkgo biloba
  Natural enhancement of energy, stamina,
  health, and libido.



All Products
Double G SuperPower, Ginko Biloba...
AntiAging/AntiOxidants
Coenzyme Q10, Royal Jelly...
Eye Health/Vision Care
Triple B Super Vision, Lutein...
Liver Protection
Milk thistle, ViaVita Lecithin...
Breath/Stomach
Herbal Breath, Stomagic...
Immune Health/ Headache
Echinacea, Bye Mygrain...
Sports and Stamina
Golden Ener-Z, DHEA, ProStamina...
Bodily Health/Tonic
Triple G Super Health, PeptiTonic...
Colon Cleansing/Weight Loss
Slim Essence, LaxaColon...
Hair Growth/Prostate Health
Hair Million, Saw Palmetto
Sleep Aid/Stress Care
Good Dream, MySerena...
For Women/menopause/PMS
Natural Wonder Woman, FeminiCare,...





Date: Tue, 07 Jan 2003 16:38:16 -0000
Subject: [hepcan] `Broken promise'_Transcript_CBC National News


Broken promise

PETER MANSBRIDGE: Canada's tainted blood tragedy spawned a painful
legacy in this country. Every day tens of thousands of Canadians live
with the consequences. Understandably, most feel deep resentment but
for some there is also a sense of abandonment, especially among
people with Hepatitis C, those not eligible for compensation. Instead
they received a government promise of help. But now years later, they
say that vow is vacant. Here's Kelly Crowe with broken promise.

KELLY CROWE (Reporter): Moose Brook, Nova Scotia, perched on the
windy coast of the Bay of Fundy, it's a long way from the complicated
business of government up in Ottawa.

RITA LAFFIN: Here kitty, kitty, kitty, kitty, kitty, kitty, kitty,
kitty, kitty.

CROWE: All Rita Laffin needed was a new hip and 12 years ago she got
one, along with a blood transfusion. She didn't know it at the time,
but she also got something else. A virus - Hepatitis C.

LAFFIN: It's just getting worse and worse and worse. And I've just
almost ready to thrown in the sponge but I'm not going to because I'm
too contrary or something.

CROWE: Rita got Hepatitis C from her transfusion and doctors
recognized it soon after her surgery. But she couldn't start taking
the drug that might have cleared the virus from her body because she
just couldn't afford it. So her doctor told her to wait until she was
65 when she would qualify for help as a senior. She's angry about
that and even angrier that she's had no help from government with the
disease that Canada's blood supply gave her.

LAFFIN: I got a lovely hip out of it though. That was a, that was
God's blessing. I got something out of it but I wouldn't have traded
my life for that hip, I'm sure and that's just about what I did.

CROWE: Rita is one of thousands of Canadians who got sick from back
blood. During the 80's and early 90's more than 2,000 people were
infected with HIV and more 48,000 others infected with Hepatitis C.
Back then no one was screaming for either virus, even though there
were warnings from other countries that something might be
contaminating the blood supply. Justice Horace Krever spent four
years pouring over the details of what went wrong. He concluded he
was health care disaster that could've been prevented if blood
officials had paid more attention to the warning signs.

JUSTICE HORACE KREVER: ...that in my view, is reasonable.

CROWE: In these boxes, Krever's final volumes with 50
recommendations. At the top of the list, no fault compensation for
all the victims.

DURHANE WONG-REIGER: We are collectively the blood system in this
country.

CROWE: Durhane Wong-Reiger had been fighting for the victims of
tainted blood for years. And five years after the Krever inquiry,
she's still at it. This time as an executive of the National Blood
Safety Council. She's still hoping Justice Krever's first
recommendation will be honoured some day.

WONG-REIGER: What he asked for was a compassionate program that
people injured through no fault of their own, through the system,
then the system is in fact obligated to provide them with
compensation. The other thing that Krever said, of course, in terms
of no fault compensation was that it should include everybody and he
meant retroactively.

CROWE: At the time these were the faces of tainted blood. HIV victims
like Janet and Randy Connors. Ottawa ended up paying millions to
hemophiliacs and others who were infected with HIV, even compensating
their infected partners and children. The story of Hepatitis C was
almost lost in the shadow.

WONG-REIGER: And when we entered into that inquiry, our primary
interest was AIDS. It was not about Hepatitis C. In fact there were
some people who wondered why in fact we even have a representation
from Hepatitis C group in this inquiry. This has nothing to do with
Hepatitis C. Sure, there may be a few people that might have gotten
Hepatitis C but one, we didn't believe it was a terribly dreadful
disease and two, we had no evidence that there were very many cases
of it. Little did we know, of course, that this was actually the much
bigger disaster.

CROWE: A disaster that came out of ignorance. Today there are tests
like this one at Toronto's Mount Sinai Hospital that can spot the
virus in the blood. But back then, little was known about Hepatitis
C. Until a decade ago, it was known only as non-A, non-B. Still,
during the 80's, other countries were developing tests to find the
mystery virus. By 1986, the U.S. was testing for it. But Canada was
not. It was Wong-Reiger who dropped the bombshell at the inquiry. A
research report that showed while the U.S. was routinely screening
its blood, Canada was doing clinical trials of the tests.

WONG-REIGER: Sat down in a hotel room in Edmonton one day and started
to read it and my initial reaction was oh my God! What this really,
in my mind, was the smoking gun. It basically said we knew that there
was a risk. We knew that there was a safety measures taken. We, you
know, instead of acting on it, we decided to set up a clinical trial
and even after we got the results, we not only didn't act on it, we
told nobody.

CROWE: Even after testing began, no one understood that tens of
thousands of Canadians would suffer long term potentially fatal
damage to their livers. No one knew then what they know now, that
Hepatitis C is a viral time bomb that only reveals itself when it's
almost too late. Dr. Kevort Peltekian is a liver specialist at the QE
II Hospital in Halifax.

DR. KEVORT PELTEKIAN (QE II Hospital, Halifax): Hepatitis C is a
virus that gets into your blood and goes and lives in the liver. In
the liver, it damages it. It uses it to build up more of its health
kind of, but at the same time it damages the liver. Now, the trouble
with this whole system is that the liver does not give you as many
symptoms as other things do. With the liver, you have to have more
than 75 percent of it damaged before the liver announces that there's
a problem with it. Hello? Hi Neil. How are you doing?

NEIL: Good. How are you?

PELTEKIAN: How are things going?

NEIL: Pretty good.

CROWE: There is only one drug that can kill the virus, a powerful and
expensive Interferon compound. But if the patient doesn't get it in
time, or if the drug doesn't kill the strain of Hepatitis C they
have, they can end up with major liver damage.

PELTEKIAN: It damages the liver and then shows up with either
cirrhosis of the liver which is scarring of the liver, with liver
failure requiring liver transplantations often or even liver cancer.

UNIDENTIFIED WOMAN (1): I didn't know I had Hepatitis C but I would
get up in the morning tired.

CROWE: Without the knowledge of their disease and with the attention
paid to HIV, those who contracted Hepatitis from Canada's blood
supply had to file a lawsuit to fight for compensation. In the end,
Ottawa came up with a $1.2 billion package, but only for those who
could prove they were infected between 1986 and 1990 when Health
Canada admits it could've been screening the blood. Rita Laffin was
left out. Today she struggles to maintain her strength, her liver
ravaged by the virus she got from tainted blood. And she had one
final piece of bad luck. Her operation was two months too late, two
months after the cutoff day, the last day of June. To Rita, it seems
especially unfair because Health Canada is still warning that there
was a risk of infected blood as late as 1992, two years after Rita's
operation because it took that long for a reliable screening test.

LAFFIN: I was two months and 17 days too late. And I just don't think
that's fair. I'm sick as any of them, I guarantee and I'm sicker than
a lot of them. I don't, I don't regret any of the other ones getting
compensation but I just think that I should have some too. And I try
not to be bitter about it and sometimes I am a little bit, and
hateful about it. But anyway...

ALLAN ROCK: And look, it's not easy. We're human beings too. We're
human beings with families.

UNIDENTIFIED MAN (1): Tell my children, please, what your
responsibility towards them when they do not have a father.

UNIDENTIFIED MAN (2): And you should be ashamed.

ROCK: I've explained the rationale.

CROWE: Rita wasn't the only one left out of the compensation and
suddenly then Health Minister Allan Rock was under pressure to help
them too.

ROCK: All of us agree that's the approach...

CROWE: So he offered them a $300 million program called Care Not
Cash. They wouldn't get any compensation. Instead they would have
their out of pocket medical expenses paid for by the provinces from
the fund. With promises made to all the Hepatitis C sufferers, Ottawa
dusted off its hands and closed the victim compensation file for
good. Not quite Justice Krever's vision of an open, compassionate, no
fault compensation plan. Not even close. And now a full five years
later, still sick from the virus they got from bad blood, some say
they're not getting the help they were promised, not really getting
much help at all. In Nova Scotia, everyone with Hepatitis C
eventually ends up here. Dr. Peltekian is the only liver specialist
east of Montreal. He says his patients have a long list of out of
pocket expenses, especially for drugs that can cost up to $30,000 a
year.

PELTEKIAN: Some individuals delay their treatments. For others, what
we've done is we've encouraged them to get into research protocols
because when they get into research protocols, there's opportunity to
use, acquire the drug as part of the research protocol.

CROWE: Do you think there's patients out there who have not received
this life saving treatment because they can't pay for it?

PELTEKIAN: Oh yes. Absolutely yes.

LAFFIN: Not one red cent. Nothing.

CROWE: That's how much Rita Laffin has received from government. No
compensation. No money for out of pocket expenses. No help with
practical expenses such as house cleaning or a driver to get her to
the doctor. Just a few months ago, she got a cheque, $6,808, her
share of a separate Red Cross class action settlement, but there's
been no sign of the promised help for out of pocket expenses. Nova
Scotia is getting $6,000,000 for people like Rita - $300,000 every
year. Jamie Muir was the Minister in charge of the money. He directed
to the everyone with Hepatitis C no matter how they got it.

JAMIE MUIR: We don't have massive numbers and to try and set up
specialized programs for a select number of people is probably not
the most effective use of that limited amount of dollars that's
flowing from the federal government.

CROWE: We've also been told by your staff that it's gone into general
revenue for acute care services.

MUIR: Well if it goes into general revenue, I think the issue is not
how in terms of the provincial books it's accounted for. The issue is
is that, are other additional resources going into the care for
people who have Hep C and the answer is yes.

CROWE: At Health Canada in Ottawa, Dr. Paul Gully says the money is
not for everyone. It's only for people who got Hepatitis C from blood
outside the compensation window to make sure they don't have to pay
out of their pocket.

DR. PAUL GULLY (Health Canada): The spirit of the undertaking was
that the money should be spend specifically for those individuals who
had acquired Hepatitis C through blood and specifically to support
their medical care. That was the spirit and those were the words of
the undertaking agreement.

CROWE: In about four years, Nova Scotia will have to tell Ottawa what
it did with the money but Muir says he's not worried.

MUIR: Clearly our people in our department, we were very, very
conscious of this when we made this decision. We did it on, you know,
basically health reasons.

CROWE: Conscious of the fact that you were breaking Ottawa's terms.

MUIR: I don't think we are. Because when we decided to go in this
direction, I mean, like I'm sure all other jurisdictions do is that
we wanted to make sure we were living out the terms and conditions of
that, of the agreement with Ottawa and we believe that we are.

CROWE: But you know you're straining somewhat from the terms that
they set out.

MUIR: Well, I don't know if we strained from it. The issue was, is to
provide care and treatment for people infected outside the window
period. We are doing that. we've been able to enhance the service
because of, we've got this additional $300,000 annually for 20 years
from Ottawa.

GULLY: We would expect as with any agreement is that the provinces
and territories, the signatures of the agreement would abide by the
spirit of that agreement. If in fact it was demonstrated after the
five year report that they did not live by the spirit of the
agreement and in fact in the meantime if there was evidence brought
forward, information brought forward to show that they had not done
that, then in fact Health Canada would, you know, look at that and
then consider, consider what it should do next.

CROWE: At the Blood Safety Conference in Toronto, Hepatitis C victims
from across Canada who were infected outside the compensation window
say they have not yet seen any sign of the Care Not Cash money
either.

VICKY BODY: They've had all this money since 1999 and none of us has
seen it. But now, okay, where is it?

CROWE: Vicky Body is from Alberta. She says she hasn't had any
government help even though she got Hepatitis C during surgery back
in 1984 and even though the illness has destroyed her accounting
career and forced her into financial ruins.

BODY: We have got, we've lost all our savings, all our retirement
income. We lost our house. We've had to file for bankruptcy twice.
And this probably sounds awful but I hope I'm dead before I have to
file it a third, I don't want to have to go through it a third time.
So if there is a Care Not Cash program, where is it? And why aren't
we benefiting from it? We're supposed to.

CROWE: For Vicky, it's bad enough she was infected two years too
early to qualify for compensation but to top it off, she says, her
disease isn't taken seriously.

BODY: I don't believe I got the right disease from the blood system.
If I had AIDS, people would be falling all over themselves to help
me. (LAUGHS) Since I have Hep C, they're not.

CROWE: Susan White also got Hepatitis C from blood, also outside the
compensation window. She's from British Columbia and she says she's
not seen the Care Not Cash money in her province either.

SUSAN WHITE: We haven't seen any of it. I've been turned down. I was
very, very sick and I was prescribed a homemaker, nutritional
supplements, vitamin supplements, bottled water and I was turned down
for all of them. And you know, my story isn't uncommon.

CROWE: This is how the Care Not Cash money is being spent across the
country. B.C., Alberta, Saskatchewan and most of the Atlantic
provinces and territories have put it into general health care
revenue. Manitoba is using it for general Hepatitis C programs.
Ontario is still deciding what to do. Quebec hasn't signed on. So
across Canada, the money is not being spent the way Ottawa promised.

WONG-REIGER: We have not gotten any provinces give us an accounting
of what they've done with those monies and there's very little
visible signs of programs and care and support for people with
Hepatitis C that has come out of those monies, even though all the
provinces have been given their share.

CROWE: Scott Heming was infected with Hepatitis C during dental
surgery right in the middle of the compensation window. That means
Ottawa admits it probably messed up in his case so he qualifies for
cash. But he says his compensation package pales compared to the one
for blood victims with HIV.

SCOTT HEMING: When they established the compensation package for HIV,
everyone got one lump sum. Everybody got the same package. They
didn't ask were you in intensive care? Right? They didn't ask are you
able to walk? Right? They didn't ask how many dependents do you have?
They simply established a package that was fair and equal for
everyone. And they should've done the exact same thing with Hepatitis
C.

CROWE: So far Scott has received $60,000 from the compensation fund.
If he wants more money, he has to prove he's getting sicker. And that
means a liver biopsy. It's dangerous for a hemophiliac like him and
he says it's not worth the risk. He thinks Ottawa should divide the
fund among all the blood victims with Hepatitis C no matter when they
were infected, especially with so much money sitting there unclaimed.

HEMING: There's $800 million still sitting of the taxpayers money.
This is taxpayers money that are sitting in a fund that support
administrators, lawyers. It was never paid out to the victims. That's
still sitting there, three years, four years later. It's still there.
This is taxpayers money. The Canadian taxpayers paid that. Pay it out
to the victims. The people outside of the window deserve compensation
as well. They got it at no fault of their own.

CROWE: Rita Laffin knows that the whole tainted blood story is back
in the news with four people now facing criminal charges. Still,
Ottawa says the case for compensation is closed. Rita is on her own.

LAFFIN: If I get anymore, I'll accept it with thanks. And if they
don't, well I'll get along without it. I'll have to. I had all the
faith in the world in Justice Krever. And I just knew he was going to
do the right thing and the man did. It's just that the other guys
didn't.

CROWE: For The National, I'm Kelly Crowe in Moose Brook, Nova Scotia.






Date: Tue, 07 Jan 2003 18:15:36 -0800
Subject: [hepcan] INFO: Desmopressin in patients undergoing hepatectomy

SourceURL:http://www.gastrohep.com/news/news.asp?id=1771

Desmopressin in patients undergoing hepatectomy

Desmopressin does not reduce intraoperative blood loss or transfusion
requirements during hepatectomy, find researchers from Hong Kong, China.

In this study, published in the Canadian Journal of Anesthesia, researchers
sought to determine the effects of desmopressin on coagulation and blood
loss in patients undergoing elective partial hepatectomy.

The research team performed a randomized, controlled and double-blind study
on 59 patients who received either 0.3 µg.kg-1 of desmopressin, or an equal
volume of normal saline.

Treatments were infused intravenously over 20 min after induction of
general anesthesia.

The researchers found a significant increase in plasma levels of factors
VIII and von Willebrand, after the infusion of study drug in both groups.

The team also observed a wide range of intraoperative blood loss (400 to
7128 ml), with no significant differences between groups.

In addition, there were no changes in plasma electrolyte levels or osmolality.

No significant difference in intraoperative blood loss between groups.

Transfusion requirements were similar in both groups.

Dr Andrew Wong's team concluded, "Desmopressin did not reduce
intraoperative blood loss or transfusion requirements during hepatectomy
despite raising clotting factor levels and improving tests of hemostasis".

Can J Anaesth 2003; 50: 14-20
08 January 2003






Date: Tue, 7 Jan 2003 17:50:50 -0600
Subject: [Hepatitis C Support Group] sounds god

White Tea

I'm sure you've heard of black and green tea, but white?



Related Resources
. Types of Tea
. Tea Brewing
. Tea Recipes


Elsewhere on the Web



Black tea has been fully fermented during processing, and green has not been fermented at all. Oolong teas are somewhere in the middle. So what is 'white tea'?

Well, just like those other teas, white tea come from the Camellia sinensis plant. But the leaves are picked and harvested before the leaves open fully, when the buds are still covered by fine white hair. Hence the name. White tea is scarcer than the other traditional teas, and quite a bit more expensive.

White tea is similar to green tea, in that it's undergone very little processing and no fermentation. But there is a noticable difference in taste. Most green teas have a distinctive 'grassy' taste to them, but white tea does not. The flavour is described as light, and sweet. You should steep white tea in water that is below the boiling point.

If you are drinking tea for your health, you may want to consider white teas. There is also considerably less caffeine in white tea than the other varieties (15mg per serving, compared to 40mg for black tea, and 20mg for green). Some studies have also shown that white tea contains more active cancer-fighting antioxidants than green tea.

As with all teas, there are many varieties of white tea, such as: white peony, golden moon, silver needle and white cloud. White teas are produced mostly in China and Japan, but the Darjeeling region of India also produces some fine white teas.


http://coffeetea.about.com/library/weekly/aa112802whitetea.htm






Date: Tue, 07 Jan 2003 18:54:38 -0000
Subject: [hephope_elist] HCV BILL IN ILLINOIS INCOMPLETE

Subject: WHAT'S WRONG with this Bill, now before the Illinois
Legislators and others like it in other states?
TO: All Veterans & HCV Organizations

CC: Illinois Senator Dan Cronin;
Illinois Rep. Angelo "Skip" Saviano;
U.S. Senator Peter Fitzgerald
U.S. Senator Richard Durbin
U.S. Rep. Danny Davis
All Illinois State Senators & Representatives
All U.S. Senators & Representatives

From: Norm Seiff, Member, VA's National HCV Community Advisory Board;
Asst. Coordinator, National HCV March on DC

RE: BILL: 92_HB3267ham001

PLEASE CONTACT YOUR STATE AND U.S. CONGRESSMEN/WOMEN IMMEDIATELY!

The original bill was written to include these sentences. Section 25.
Veterans' Affairs. On or before March 1,
7 2002, the Director of Veterans' Affairs shall report to the
8 Department of Public Health regarding efforts to educate,
9 screen, and treat veterans who carry the hepatitis C virus.

But the House amended it and took out any reference to veterans what
so ever. In it's place they put testing of prisons, which is good,
but, The State of Illinois and other States doesn't recognize
Veterans.............Then why should the VA!

In WA State the legislation originally stated that the VA was to be
given as much say as the University of Washington Medical for
distributed educational literature, but the VA rep Skip Drepps (Vets
with Disabilities) was at the work sessions and declined,. said NOT
to include the VA in the plan since all their education etc. came
from the UW anyway.

HepCAlert is having the same trouble with the VA. They will not allow
HepCAlert to included in published support material anything that
references Veterans are at higher risk than the general public.

Why can't these bills call for testing of veterans? I think it is a
consorted effort by the VA to continue to downplay the seriousness of
HCV among vets. What are we fighting for if we can't get legislation
to recognize the seriousness of veteran infection rates?


3,441,750 civilians of which 2,547,070 are Veterans with HCV
Approximately 75% of reported people with Hepatitis C Are Veterans.

1,410,750 are Vietnam War Vets.

Thousands of Veterans will die this year because of Hepatitis C.

450,000 veterans are expected to develop cirrhosis, of which 90,000
will develop cancer NOW!

Most Veterans do not think they need to be tested.

References:
Most Americans with HCV
Are Veterans.
http://hcvets.com/index.html

450,000 will be veterans
http://hcvets.com/index.html

Testimony of Gary A. Roselle, M. D. Program Director for Infectious
Diseases Veterans Health Administration Department of Veterans
Affairs Before the Subcommittee on Benefits Committee on Veterans'
Affairs U.S. House of Representatives April 13, 2000
http://hcvets.com/data/va_news/testimony_of_gary_a.htm

HCVets.com Transmission Methods for HCV
http://hcvets.com/data/transmission_methods/transmission.htm

Veterans' Health Care: Observations on VA's Assessment of
Hepatitis C Budgeting and Funding (25-APR-01, GAO-01-661T).
http://frwebgate.access.gpo.gov/cgi-bin/useftp.cgi?
IPaddress=162.140.64.21&filename=d01661t.txt&directory=/diskb/wais/dat
a/gao


This is an excerpt from a current bill in IL. 92_HB3267
http://www.legis.state.il.us/legisnet/legisnet92/hbgroups/hb/920HB3267
.html AN ACT in relation to health.
We are so appalled by this.

We're getting the people to finally write what we need and it is
being rejected.

2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly
The house has amended the act to exclude the follow.

6 Section 25. Veterans' Affairs. On or before March 1,
7 2002, the Director of Veterans' Affairs shall report to the
8 Department of Public Health regarding efforts to educate,
9 screen, and treat veterans who carry the hepatitis C virus.

92_HB3267ham001
This is the final copy and they did away with help for vets.
http://www.legis.state.il.us/legisnet/legisnet92/hbgroups/hb/920HB3267
ham001.html


State of Illinois
92nd General Assembly
Legislation
Original Bill
92_HB3267


LRB9204544DJgc

1 AN ACT in relation to health.

2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:

4 Section 1. Short title. This Act may be cited as the
5 Hepatitis C Public Awareness Act.

6 Section 5. Findings; intent.
7 (a) The General Assembly finds and declares all of the
8 following:
9 (1) Hepatitis C is classified as a silent killer,
10 where no recognizable signs or symptoms occur until
11 severe liver damage has occurred.
12 (2) Hepatitis C has been characterized by the World
13 Health Organization as a disease of primary concern to
14 humanity.
15 (3) Studies indicate that 1.8% of the population,
16 nearly 4,000,000 million Americans, carry the virus HCV
17 that causes hepatitis C. In Illinois, as many as 200,000
18 individuals may be carriers and could develop the
19 debilitating and potentially deadly liver disease
20 associated with hepatitis C in their lifetime. An expert
21 panel, convened by the National Institutes of Health,
22 estimated that 30,000 acute new infections occur each
23 year in the United States, and only 25 to 30 percent of
24 those are diagnosed. Current data sources indicate that
25 8,000 to 10,000 Americans die from hepatitis C each year.
26 (4) Studies also indicate that inmates in
27 correctional facilities have a higher incidence of
28 hepatitis C than the general population. Upon their
29 release from prison, these inmates present a significant
30 health risk to the general population.
31 (b) It is the intent of the General Assembly to study the

-2- LRB9204544DJgc
1 adequacy of the health care delivery system as it pertains to
2 hepatitis C.
3 (c) It is the intent of the General Assembly to urge the
4 Department of Public Health to make moneys available to
5 community-based not-for-profit organizations for education
6 and outreach with respect to the hepatitis C virus.

7 Section 10. Public education and outreach.
8 (a) The Director of Public Health shall develop and
9 implement a public education and outreach program to raise
10 awareness of the hepatitis C virus. The program shall be
11 aimed at high-risk groups, physicians' offices, health care
12 workers, and health care facilities. The program shall do
13 all of the following:
14 (1) Attempt to coordinate with national public
15 education efforts related to the identification and
16 notification of recipients of blood from
17 hepatitis-C-virus-positive donors.
18 (2) Attempt to stimulate interest in and coordinate
19 with community-based organizations to sponsor community
20 forums, and undertake other appropriate community
21 outreach activities.
22 (3) Employ public communication strategies utilizing
23 a variety of media that may include, but need not be
24 limited to, print, radio, television, and the Internet.
25 (b) The Director of Public Health shall include
26 information on co-infection of human immunodeficiency virus
27 (HIV) or hemophilia with the hepatitis C virus in the
28 professional training and all appropriate care and treatment
29 programs under the jurisdiction of the Department.
30 (c) The Director of Public Health shall develop a program
31 to work with the Department of Corrections to identify
32 hepatitis-C-virus-positive inmates likely to be released
33 within 2 years and provide counseling and treatment options

-3- LRB9204544DJgc
1 to reduce the community risk.
2 (d) The Director of Public Health shall urge local public
3 health officials to make hepatitis C virus screening
4 available for uninsured individuals upon request.
5 (e) The Director of Public Health shall include hepatitis
6 C counseling, education, and testing, as appropriate, in
7 local State-funded programs, including those addressing HIV,
8 tuberculosis, sexually transmitted disease, and all other
9 appropriate programs approved by the Director.

10 Section 15. Health professionals and community service
11 providers.
12 (a) The Department of Public Health shall make protocols
13 and guidelines on hepatitis C developed by the National
14 Institutes of Health available for educating physicians and
15 health professionals and training community service providers
16 on the most recent scientific and medical information on
17 hepatitis C detection, transmission, diagnosis, treatment,
18 and therapeutic decisionmaking.
19 (b) The guidelines may include, but need not be limited
20 to, the following:
21 (1) Tracking and reporting of both acute and chronic
22 cases of hepatitis C by public health officials.
23 (2) A cost-efficient plan to screen the prison
24 population and the medically indigent population.
25 (3) Protocols within the Department of Corrections
26 to enable that Department to provide appropriate
27 prevention and treatment to prisoners with hepatitis C.
28 (4) Protocols for the education of correctional
29 peace officers and other correctional workers who work
30 with prisoners with hepatitis C.
31 (5) Protocols for public safety and health care
32 workers who come into contact with hepatitis C patients.
33 (6) Surveillance programs to determine the

-4- LRB9204544DJgc
1 prevalence of hepatitis C in ethnic and other high-risk
2 populations.
3 (7) Education and outreach programs for high-risk
4 individuals, including, but not limited to, individuals
5 who received blood transfusions before 1992,
6 hemophiliacs, veterans, women who underwent a caesarian
7 section or premature delivery before 1990, persons who
8 received an organ transplant before 1990, persons who
9 receive invasive cosmetic procedures, including body
10 piercing and tattooing, students, minority communities,
11 and any other categories of persons at high risk for
12 hepatitis C infection as determined by the Director of
13 Public Health. Education and outreach programs shall be
14 targeted to high-risk individuals as determined by the
15 Director. Education programs may provide information and
16 referrals on hepatitis C, including, but not limited to,
17 education materials developed by health-related companies
18 or community-based or national advocacy organizations,
19 and referrals to advocacy organizations, counseling or
20 patient support groups, and existing hotlines for
21 consumers.
22 (c) Nothing in this Section shall be construed to require
23 the Department of Public Health to develop or produce any
24 protocol, guideline, or proposal.

25 Section 20. Corrections. The Director of Corrections
26 shall do all of the following:
27 (1) On or before March 1, 2002, provide the
28 Department of Public Health with an annual statistical
29 report on the prevalence of the hepatitis C virus in
30 correctional facilities in this State and trends in the
31 incidence and prevalence of the hepatitis C virus in the
32 correctional system.
33 (2) Establish and make available a voluntary program

-5- LRB9204544DJgc
1 to test inmates for the presence of the hepatitis C virus
2 upon incarceration and in conjunction with any routine
3 blood testing.
4 (3) Update treatment protocols and regimens as new
5 therapies become available.

6 Section 25. Veterans' Affairs. On or before March 1,
7 2002, the Director of Veterans' Affairs shall report to the
8 Department of Public Health regarding efforts to educate,
9 screen, and treat veterans who carry the hepatitis C virus.

Amended by the House

92_HB3267ham001
LRB9204544DJdvam01

1 AMENDMENT TO HOUSE BILL 3267

2 AMENDMENT NO. . Amend House Bill 3267 on page 4,
3 line 6, by deleting "veterans,"; and

4 on page 5, by deleting lines 6 through 9.

Sent to the Senate

92_HB3267eng


HB3267 Engrossed LRB9204544DJgc

1 AN ACT in relation to health.

2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:

4 Section 1. Short title. This Act may be cited as the
5 Hepatitis C Public Awareness Act.

6 Section 5. Findings; intent.
7 (a) The General Assembly finds and declares all of the
8 following:
9 (1) Hepatitis C is classified as a silent killer,
10 where no recognizable signs or symptoms occur until
11 severe liver damage has occurred.
12 (2) Hepatitis C has been characterized by the World
13 Health Organization as a disease of primary concern to
14 humanity.
15 (3) Studies indicate that 1.8% of the population,
16 nearly 4,000,000 Americans, carry the virus HCV that
17 causes hepatitis C. In Illinois, as many as 200,000
18 individuals may be carriers and could develop the
19 debilitating and potentially deadly liver disease
20 associated with hepatitis C in their lifetime. An expert
21 panel, convened by the National Institutes of Health,
22 estimated that 30,000 acute new infections occur each
23 year in the United States, and only 25 to 30 percent of
24 those are diagnosed. Current data sources indicate that
25 8,000 to 10,000 Americans die from hepatitis C each year.
26 (4) Studies also indicate that inmates in
27 correctional facilities have a higher incidence of
28 hepatitis C than the general population. Upon their
29 release from prison, these inmates present a significant
30 health risk to the general population.
31 (b) It is the intent of the General Assembly to study the

HB3267 Engrossed -2- LRB9204544DJgc
1 adequacy of the health care delivery system as it pertains to
2 hepatitis C.
3 (c) It is the intent of the General Assembly to urge the
4 Department of Public Health to make moneys available to
5 community-based not-for-profit organizations for education
6 and outreach with respect to the hepatitis C virus.

7 Section 10. Public education and outreach.
8 (a) The Director of Public Health shall develop and
9 implement a public education and outreach program to raise
10 awareness of the hepatitis C virus. The program shall be
11 aimed at high-risk groups, physicians' offices, health care
12 workers, and health care facilities. The program shall do
13 all of the following:
14 (1) Attempt to coordinate with national public
15 education efforts related to the identification and
16 notification of recipients of blood from
17 hepatitis-C-virus-positive donors.
18 (2) Attempt to stimulate interest in and coordinate
19 with community-based organizations to sponsor community
20 forums, and undertake other appropriate community
21 outreach activities.
22 (3) Employ public communication strategies utilizing
23 a variety of media that may include, but need not be
24 limited to, print, radio, television, and the Internet.
25 (b) The Director of Public Health shall include
26 information on co-infection of human immunodeficiency virus
27 (HIV) or hemophilia with the hepatitis C virus in the
28 professional training and all appropriate care and treatment
29 programs under the jurisdiction of the Department.
30 (c) The Director of Public Health shall develop a program
31 to work with the Department of Corrections to identify
32 hepatitis-C-virus-positive inmates likely to be released
33 within 2 years and provide counseling and treatment options

HB3267 Engrossed -3- LRB9204544DJgc
1 to reduce the community risk.
2 (d) The Director of Public Health shall urge local public
3 health officials to make hepatitis C virus screening
4 available for uninsured individuals upon request.
5 (e) The Director of Public Health shall include hepatitis
6 C counseling, education, and testing, as appropriate, in
7 local State-funded programs, including those addressing HIV,
8 tuberculosis, sexually transmitted disease, and all other
9 appropriate programs approved by the Director.

10 Section 15. Health professionals and community service
11 providers.
12 (a) The Department of Public Health shall make protocols
13 and guidelines on hepatitis C developed by the National
14 Institutes of Health available for educating physicians and
15 health professionals and training community service providers
16 on the most recent scientific and medical information on
17 hepatitis C detection, transmission, diagnosis, treatment,
18 and therapeutic decision making.
19 (b) The guidelines may include, but need not be limited
20 to, the following:
21 (1) Tracking and reporting of both acute and chronic
22 cases of hepatitis C by public health officials.
23 (2) A cost-efficient plan to screen the prison
24 population and the medically indigent population.
25 (3) Protocols within the Department of Corrections
26 to enable that Department to provide appropriate
27 prevention and treatment to prisoners with hepatitis C.
28 (4) Protocols for the education of correctional
29 peace officers and other correctional workers who work
30 with prisoners with hepatitis C.
31 (5) Protocols for public safety and health care
32 workers who come into contact with hepatitis C patients.
33 (6) Surveillance programs to determine the

HB3267 Engrossed -4- LRB9204544DJgc
1 prevalence of hepatitis C in ethnic and other high-risk
2 populations.
3 (7) Education and outreach programs for high-risk
4 individuals, including, but not limited to, individuals
5 who received blood transfusions before 1992,
6 hemophiliacs, women who underwent a caesarian section or
7 premature delivery before 1990, persons who received an
8 organ transplant before 1990, persons who receive
9 invasive cosmetic procedures, including body piercing and
10 tattooing, students, minority communities, and any other
11 categories of persons at high risk for hepatitis C
12 infection as determined by the Director of Public Health.
13 Education and outreach programs shall be targeted to
14 high-risk individuals as determined by the Director.
15 Education programs may provide information and referrals
16 on hepatitis C, including, but not limited to, education
17 materials developed by health-related companies or
18 community-based or national advocacy organizations, and
19 referrals to advocacy organizations, counseling or
20 patient support groups, and existing hotlines for
21 consumers.
22 (c) Nothing in this Section shall be construed to require
23 the Department of Public Health to develop or produce any
24 protocol, guideline, or proposal.

25 Section 20. Corrections. The Director of Corrections
26 shall do all of the following:
27 (1) On or before March 1, 2002, provide the
28 Department of Public Health with an annual statistical
29 report on the prevalence of the hepatitis C virus in
30 correctional facilities in this State and trends in the
31 incidence and prevalence of the hepatitis C virus in the
32 correctional system.
33 (2) Establish and make available a voluntary program

HB3267 Engrossed -5- LRB9204544DJgc
1 to test inmates for the presence of the hepatitis C virus
2 upon incarceration and in conjunction with any routine
3 blood testing.
4 (3) Update treatment protocols and regimens as new
5 therapies become available






Date: Tue, 7 Jan 2003 23:54:40 -0500
Subject: [Compassion] Rhematoid Arthritis Med for Qualified People


ABBOTT LABORATORIES ANNOUNCES UNPRECEDENTED DRUG ACCESS PROGRAM FOR NEW RHEUMATOID ARTHRITIS (RA) DRUG, HUMIRA™ (ADALIMUMAB), FOR MEDICARE-ELIGIBLE SENIORS


Abbott Park, Illinois, January 6, 2003—

Abbott Laboratories today announced the launch of the HUMIRA Medicare Assistance Program, an unprecedented drug access program that will provide its newly approved rheumatoid arthritis (RA) drug, HUMIRA™ (pronounced Hu-'mare-ah) (adalimumab) (pronounced a-da-'lim-yoo-mab), at no cost to Medicare-eligible seniors without prescription drug coverage until a Medicare drug benefit is enacted. HUMIRA, recently approved by the FDA, is the first human monoclonal antibody approved for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active RA who have had insufficient response to one or more traditional disease modifying antirheumatic drugs (DMARDs). HUMIRA was created using phage display technology, resulting in an antibody with human-derived heavy and light chains variable regions and human IgG1:K constant regions.

"HUMIRA is an example of the positive impact pharmaceutical innovation can have for people living with chronic and debilitating conditions like RA," said Miles D. White, chairman and chief executive officer, Abbott Laboratories. "To reinforce Abbott's commitment to providing access to our medications, we’re initiating the HUMIRA Medicare Assistance Program to help remove barriers to this important new medicine for seniors with RA."

Abbott’s HUMIRA Medicare Assistance Program ensures that Medicare-eligible seniors in need of a biologic treatment for RA who do not have prescription drug coverage will be able to receive HUMIRA at no cost until a Medicare prescription drug benefit is enacted. Seniors interested in the program should talk with their health care provider. Eligible seniors will receive HUMIRA directly from their health care provider, and access will continue as long as they continue to meet the eligibility criteria. More information is available by calling 1-866-4-HUMIRA.

"We always encourage companies to give seniors in need access to FDA approved drugs, like Abbott is doing with this new program," said Secretary Tommy G. Thompson, U.S. Department of Health and Human Services. "It is a top priority for the Administration to work with Congress to get a prescription drug benefit and I appreciate Abbott's support of that priority."

"Comprehensive Medicare reform with an affordable prescription drug benefit remains one of my top priorities in the 108th Congress," said Sen. John Breaux (D-La.). "I applaud Abbott's efforts to provide affordable medication options to seniors who are limited by current Medicare reimbursement. Until Medicare provides coverage for prescription drugs, programs like the HUMIRA Medicare Assistance Program are good short-term solutions to improve access to newer treatments."

"We applaud Abbott for its successful development of HUMIRA for the treatment of rheumatoid arthritis and the company's commitment to ensuring that Medicare recipients have access to this therapy," said Rep. Mark Kirk, (R-IL). "Abbott's commitment to provide this drug to all Medicare recipients who do not have access to any form of drug reimbursement plan is a further testament to their caring and compassionate approach until a Medicare prescription drug benefit is passed by Congress."

"As a rheumatologist, it's important to be able to make treatment decisions based on the appropriate medicine for the patient, not based on their prescription drug coverage," said Yvonne Sherrer, M.D., medical director and director of clinical research at the Center for Rheumatology, Immunology and Arthritis in Fort Lauderdale, Florida. "Abbott's HUMIRA Medicare Assistance Program allows me to be able to have this new medicine as an option, even for patients who don't have prescription drug coverage."

In addition to the HUMIRA Medicare Assistance Program, Abbott is offering reimbursement information support through the HUMIRA Resource Center. Through this resource center, patients with RA can find out about their options for prescription coverage for HUMIRA through private insurance or eligibility for federal and state assistance programs, as well as other Abbott programs. Abbott has a Patient Assistance Program for patients in need who meet specific financial criteria to receive HUMIRA at no cost.

Important Safety Information
Cases of tuberculosis (TB), frequently disseminated or extra pulmonary at clinical presentation have been observed in patients receiving HUMIRA. Serious infections and sepsis, including fatalities, have been reported with the use of TNF-blocking agents, including HUMIRA. Many of these infections occurred in patients on concomitant immunosuppressive therapy that in addition to their underlying disease could predispose them to infections. Other invasive opportunistic fungal infections have also been observed in patients treated with TNF-blocking agents, including HUMIRA.

TNF-blocking agents, including HUMIRA, have been associated in rare cases with exacerbation of demyelinating disease. The most frequent adverse events seen in the placebo-controlled clinical trials (HUMIRA vs. placebo) were upper respiratory infection (17 percent vs. 13 percent), injection site pain (12 percent vs. 12 percent), headache (12 percent vs. 8 percent), rash (12 percent vs. 6 percent) and sinusitis (11 percent vs. 9 percent). Discontinuations due to adverse events were 7 percent for HUMIRA and 4 percent for placebo. As with any treatment program, the benefits and risks of HUMIRA should be carefully considered before initiating therapy.

About RA
More than five million people worldwide suffer from RA, a
chronic autoimmune disease that causes pain, swelling and stiffness in the
joints of hands, feet and wrists, and often leads to the destruction of
joints. Unlike osteoarthritis, the most common form of arthritis, RA is an
autoimmune disease where joints are inflamed, resulting in eventual
destruction of the joint's interior and the surrounding bone.

The long-term prognosis for patients with RA is poor, and as a result, many patients face increased disability and premature death. Patients interested in more information about RA can visit the Web site, www.RA.com.

Abbott's Commitment to Immunology

Abbott is focused on the discovery and development of innovative treatments for immunologic diseases. Founded in 1989, the Abbott Bioresearch Center in Worcester, Massachusettsis a world-class discovery and basic research facility committed to finding new treatments for autoimmune diseases.

Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals, and medical products, including devices and diagnostics. The company employs approximately 70,000 people and markets its products in more than 130 countries.

More information about Abbott Immunology and HUMIRA, including full prescribing information, is available on the Web sites, www.abbottimmunology.com and www.HUMIRA.com.


  • Hepatitis and Health information and news resources
  • DreamPharm: herb mint
  • Aphrodisiac food for Valentine Day
  • Skin care cream e-mail scrap
  • Health information from e-mail scraps
  • Hepatitis information and various health issues from e-mail scraps
  • Hair loss: alopecia information from e-mail scraps
  • Various health information gleaned from e-mail scrap
  • Hepatitis drug information gleaned from e-mail messages
  • Stem cell info from e-mail scrap
  • Hair care info from e-mail scrap
  • Hepatitis drug information gleaned from e-mail messages
  • Hepatitis drug information gleaned from e-mail messages
  • Alopecia treatment opinions and personal experiences gleaned from e-mail scraps
  • Stem cell and human clone: opinion and information from e-mail scrap
  • Hepatitis related information from e-mail collection
  • Chronic illnesses information from e-mail collection
  • Stem cell research information from e-mail letters
  • Hepatitis c and liver fibrosis info from e-mail collection
  • Hepatitis C and various health issues: e-mail excerpts



    • The information provided at DreamPharm.com is not intended for self-diagnosis nor self-treatment of conditions that should be managed by a qualified health care provider. Unless otherwise indicated, research, ailment and product information have not been evaluated by the US Food and Drug Administration ("FDA").


    New Registration
    Sign In
    Search  ||  Site Map  ||  Security & Privacy  ||  Legal  ||  Home  || 
    Hair Million, Inc.